SLS vs SLXN

SELLAS Life Sciences Group, Inc vs Silexion Therapeutics Corp — Valuation Comparison 2026

SLS

Biotechnology
SELLAS Life Sciences Group, Inc
Quality
4.1
out of 10
Value Trap
18
SAFE
Price
$9.18
Last close
Models
7/13
Active
VS

SLXN

Biotechnology
Silexion Therapeutics Corp
Quality
5.3
out of 10
Value Trap
18
SAFE
Price
$0.43
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType SLS Fair ValueSLS Upside SLXN Fair ValueSLXN Upside
Bayesian DCF Intrinsic $2.78 -69.8% $0.38 -10.3%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.65 -92.9% $1.51 +252.8%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for SLS vs SLXN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SLS vs SLXN — Which Stock Is More Undervalued?

SLXN scores higher with a 5.3/10 quality rating vs SLS's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing SELLAS Life Sciences Group, Inc (SLS) and Silexion Therapeutics Corp (SLXN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SLS currently trades at $9.18 with a QOC of 4.1/10, while SLXN trades at $0.43 with a QOC of 5.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).